|

GFH009 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1/2: 2

Top Sponsors

  • Genfleet Therapeutics (Shanghai) Inc.2

Indications

  • Cancer2
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)1
  • Large B-cell Lymphoma1

Other2 trials

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/2
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.